Alexander A. Cohen

This paper introduces Duality vaccination, a method that delivers both activating and inhibitory stimuli to shape antibody responses, using nanoparticle-based immunogens.

This paper develops mRNA-based vaccines encoding RBD quartets and shows they match or improve antibody breadth, T-cell responses, and epitope targeting compared to protein-based vaccines.

This paper develops a recombinant single-cycle influenza viral vector vaccine against SARS-CoV-2 and SARS-like betacoronaviruses, showing robust immune responses in mice.

This study evaluates ALD-delivered mosaic-8b RBD-nanoparticles, showing improved cross-reactive antibody responses against mismatched sarbecoviruses compared to conventional immunizations.

This study evaluates bivalent S-EABR mRNA-LNP boosters in pre-vaccinated mice, showing enhanced neutralizing responses and polyclass RBD antibody diversity against SARS-CoV-2 variants.

This paper develops mosaic RBD-nanoparticles to induce cross-reactive anti-sarbecovirus antibodies in animals, demonstrating their effectiveness against SARS-CoV-2 variants and zoonotic viruses.

The paper designs mosaic nanoparticles with SARS-like betacoronavirus RBDs to enhance cross-reactive immune responses in mice, finding that mosaic-7COM elicits stronger responses against zoonotic sarbecoviruses and Omicrons.

The paper shows mosaic-8b nanoparticles induce broader cross-reactive antibodies than homotypic ones, even in pre-vaccinated animals, suggesting potential for improved vaccine design against emerging sarbecoviruses.